Abstract
Locally advanced disease accounts for 5–15% of the differentiated thyroid cancer (DTC) patients. Although surgical excision of the entire primary lesion is aimed for the optimum disease management, incomplete resections may occur especially in patients having invasions to recurrent laryngeal nerve, respiratory tract, esophagus, or major vessels. Radioactive iodine (RAI) treatment is the primary adjuvant therapy modality in high-risk DTC cases. In cases with RAI-resistant disease, external beam radiotherapy (EBRT) may be an alternative. However, its role is debated due to the lack of prospective data and also conflicting results in retrospective studies. Since EBRT may have some severe side effects, the consequences of uncontrolled disease and the potential complications of EBRT should be considered comparatively.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Nixon IJ, Simo R, Newbold K, Rinaldo A, Suarez C, Kowalski LP, et al. Management of invasive differentiated thyroid cancer. Thyroid. 2016;26:1156–66. https://doi.org/10.1089/thy.2016.0064.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. https://doi.org/10.1089/thy.2015.0020.
Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. A systematic review and meta-analysis of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2002;89:3668–76.
Sacks W, Fung CH, Chang JR, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20:1235–45. https://doi.org/10.1089/thy.2009.0455.
Kowalski LP, Filho JG. Results of the treatment of locally invasive thyroid carcinoma. Head Neck. 2002;24(4):340.
Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879–85.
Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab. 2002;87:1521–6.
Kiess AP, Agrawal N, Brierley JD, Duvvuri U, Ferris RL, Genden E, et al. External-beam radiotherapy for differentiated thyroid cancer locoregional control: a statement of the American Head and Neck Society. Head Neck. 2016;38:493–8. https://doi.org/10.1002/hed.24357.
Fussey JM, Crunkhorn R, Tedla M, Weickert MO, Mehanna H. External beam radiotherapy in differentiated thyroid carcinoma: a systematic review. Head Neck. 2016;38:2297–305.
Perros P, Colley S, Boelaert K, Evans C, Evans RM, Gerrard GE, et al. British Thyroid Association guidelines for the management of thyroid cancer. Clin Endocrinol. 2014;81(Suppl):1.
Chow SM, Yau S, Kwan CK, Poon PC, Law SC. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr Relat Cancer. 2006;13:1159–72.11.
Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009;74:1083–91. https://doi.org/10.1016/j.ijrobp.2008.09.023.
Tuttle RM, Rondeau G, Lee NY. A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer. Cancer Control. 2011;18:89–95.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Yararbaş, Ü., Özcan, Z. (2019). A Case of a Papillary Thyroid Cancer with Gross Residual Disease After Surgery. In: Özülker, T., Adaş, M., Günay, S. (eds) Thyroid and Parathyroid Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-78476-2_40
Download citation
DOI: https://doi.org/10.1007/978-3-319-78476-2_40
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-78475-5
Online ISBN: 978-3-319-78476-2
eBook Packages: MedicineMedicine (R0)